JP2014512333A5 - - Google Patents

Download PDF

Info

Publication number
JP2014512333A5
JP2014512333A5 JP2013549539A JP2013549539A JP2014512333A5 JP 2014512333 A5 JP2014512333 A5 JP 2014512333A5 JP 2013549539 A JP2013549539 A JP 2013549539A JP 2013549539 A JP2013549539 A JP 2013549539A JP 2014512333 A5 JP2014512333 A5 JP 2014512333A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
metformin
composition according
compound
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013549539A
Other languages
English (en)
Other versions
JP5911514B2 (ja
JP2014512333A (ja
Filing date
Publication date
Priority claimed from US13/348,265 external-priority patent/US20120178813A1/en
Application filed filed Critical
Publication of JP2014512333A publication Critical patent/JP2014512333A/ja
Publication of JP2014512333A5 publication Critical patent/JP2014512333A5/ja
Application granted granted Critical
Publication of JP5911514B2 publication Critical patent/JP5911514B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (10)

  1. トホルミンとドコサヘキサエン酸との塩、またはメトホルミンとエイコサペンタエン酸およびドコサヘキサエン酸の混合物との塩である、化合物
  2. 請求項1に記載の化合物、および薬学的に許容可能な担体、ビヒクル、または希釈剤を含む、医薬組成物。
  3. 請求項1に記載の化合物または請求項2に記載の医薬組成物を含む単位剤形、使のための指示および前記単位剤形を収容するための少なくとも1つの容器を含むキット。
  4. 糖尿病、トリグリセリドの上昇、前糖尿病、肥満、心不整脈、心筋症または心筋梗塞から選択される哺乳類の症状を治療するための、請求項に記載の医薬組成物。
  5. a)好適なメトホルミン塩からメトホルミンの遊離塩基を新しく調製すること;およびb)新しく調製したメトホルミンの遊離塩基を、ドコサヘキサエン酸、またはエイコサペンタエン酸およびドコサヘキサエン酸の混合物と、1℃から60℃の間の温度で反応させることを含む、請求項1に記載の化合物を製造するための方法。
  6. 治療が必要である被験者の血清トリグリセリドを低下するための、請求項2に記載の医薬組成物。
  7. 前記被験者が、200mg/dLを超える血清トリグリセリド濃度を有する、請求項6に記載の医薬組成物。
  8. 前記被験者が高トリグリセリド血症である、請求項6に記載の医薬組成物。
  9. 前記被験者が、発展中の糖尿病、前糖尿病状態、肥満、心不整脈、心筋梗塞、および高血清トリグリセリド濃度に起因する脳卒中を示す、またはこれらのリスクを有する被験者からなる群からさらに選択される、請求項6に記載の医薬組成物。
  10. 以下の工程:
    アセトニトリル中のメトホルミン遊離塩基の濃縮溶液に、ドコサヘキサエン酸、またはエイコサペンタエン酸およびドコサヘキサエン酸の混合物を室温で滴下して加える工程、
    反応混合物を、光から防護された容器中で、1時間室温で撹拌する工程、
    前記反応混合物を、1時間、0℃で冷却する工程、および
    冷却された前記反応混合物を窒素雰囲気下で濾過し、粉末になるまで乾燥させる工程、
    を含む、請求項1に記載の化合物を製造する方法。
JP2013549539A 2011-01-12 2012-01-12 脂質低下抗糖尿病薬 Expired - Fee Related JP5911514B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161461113P 2011-01-12 2011-01-12
US61/461,113 2011-01-12
US13/348,265 2012-01-11
US13/348,265 US20120178813A1 (en) 2011-01-12 2012-01-11 Lipid-lowering antidiabetic agent
PCT/US2012/021070 WO2012097144A1 (en) 2011-01-12 2012-01-12 Lipid-lowering antidiabetic agent

Publications (3)

Publication Number Publication Date
JP2014512333A JP2014512333A (ja) 2014-05-22
JP2014512333A5 true JP2014512333A5 (ja) 2015-03-12
JP5911514B2 JP5911514B2 (ja) 2016-04-27

Family

ID=46455756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013549539A Expired - Fee Related JP5911514B2 (ja) 2011-01-12 2012-01-12 脂質低下抗糖尿病薬

Country Status (12)

Country Link
US (4) US20120178813A1 (ja)
EP (1) EP2663186A4 (ja)
JP (1) JP5911514B2 (ja)
KR (1) KR20140092228A (ja)
CN (1) CN103533833B (ja)
AU (1) AU2012205547B2 (ja)
BR (1) BR112013017845A2 (ja)
CA (1) CA2824192A1 (ja)
EA (1) EA201391028A1 (ja)
IL (1) IL227346A0 (ja)
MX (1) MX2013008131A (ja)
WO (1) WO2012097144A1 (ja)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
US8765811B2 (en) 2012-07-10 2014-07-01 Thetis Pharmaceuticals Llc Tri-salt form of metformin
WO2014011814A1 (en) * 2012-07-10 2014-01-16 Thetis Pharmaceuticals Llc Tri-salt form of metformin
US9382187B2 (en) 2012-07-10 2016-07-05 Thetis Pharmaceuticals Llc Tri-salt form of metformin
WO2014080307A2 (en) * 2012-11-21 2014-05-30 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
WO2014195810A2 (en) * 2013-06-04 2014-12-11 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
EP3004049B1 (en) * 2013-06-04 2018-09-05 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
WO2015022613A1 (en) * 2013-08-11 2015-02-19 Mahesh Kandula Compositions and methods for the treatment of diabetes and pre-diabetes
EP3140316A1 (en) * 2014-05-05 2017-03-15 Thetis Pharmaceuticals LLC Compositions and methods relating to ionic salts of peptides
DK3157936T3 (en) 2014-06-18 2019-02-04 Thetis Pharmaceuticals Llc MINERAL AMINO ACID ACID COMPLEXES OF ACTIVE SUBSTANCES
US9242008B2 (en) 2014-06-18 2016-01-26 Thetis Pharmaceuticals Llc Mineral amino-acid complexes of fatty acids
WO2016132186A1 (en) * 2015-02-20 2016-08-25 Mohan M Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
US9371276B1 (en) * 2015-03-21 2016-06-21 Mohan Murali Alapati Compositions and methods for the treatment of hyperglycemia and metabolic syndrome
EP3454907B1 (en) 2016-06-03 2020-07-22 Thetis Pharmaceuticals LLC Compositions and methods relating to salts of specialized pro-resolving mediators of inflammation
EP3648748A1 (en) 2017-07-06 2020-05-13 Evonik Operations GmbH Enteric coated solid dosage form comprising omega-3 fatty acid amino acid salts
JP7050148B2 (ja) 2017-08-15 2022-04-07 エボニック オペレーションズ ゲーエムベーハー オメガ-3脂肪酸アミノ酸塩の有効成分含有量が高い錠剤
WO2019120111A1 (zh) * 2017-12-18 2019-06-27 镇学初 二甲双胍盐在治疗脑梗死中的用途
CN114206135A (zh) 2019-08-08 2022-03-18 赢创运营有限公司 用于生产多不饱和脂肪酸盐的下游工艺
US20220287345A1 (en) 2019-08-08 2022-09-15 Evonik Operations Gmbh Solubility enhancement of poorly soluble actives
CN113105367B (zh) * 2021-03-30 2022-08-02 广州大学 一类二甲双胍盐及其制备方法和应用
CN116999398A (zh) * 2022-06-30 2023-11-07 山东海赜生物科技有限公司 一种口服组合物

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6720001B2 (en) 1999-10-18 2004-04-13 Lipocine, Inc. Emulsion compositions for polyfunctional active ingredients
ATE345122T1 (de) 2000-02-04 2006-12-15 Takeda Pharmaceutical Stabile emulsionszubereitungen
US6491950B1 (en) 2000-08-07 2002-12-10 Kos Pharmaceuticals, Inc. Controlled release pharmaceutical composition
US6667064B2 (en) 2000-08-30 2003-12-23 Pilot Therapeutics, Inc. Composition and method for treatment of hypertriglyceridemia
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
FR2818906B1 (fr) * 2000-12-29 2004-04-02 Dospharma Association medicamenteuse d'une biguanine et d'un transporteur, par exemple de metformine et d'arginine
DE10102050A1 (de) 2001-01-17 2002-07-18 Basf Ag Zubereitung zur Verbesserung der Nahrungsverwertung
US6881854B2 (en) 2001-03-29 2005-04-19 Basf Aktiengesellschaft Conjugated unsaturated glyceride mixtures and a method for producing the same
EP1429602B1 (en) 2001-08-31 2009-12-16 Rutgers, The State University Of New Jersey Methods for treating disorders using plant extracts
ITMI20012384A1 (it) 2001-11-12 2003-05-12 Quatex Nv Uso di acidi grassi poliinsaturi per la prevenzione primaria di eventi cardiovascolari maggiori
AU2003211131A1 (en) * 2002-02-14 2003-09-04 Sonus Pharmaceuticals, Inc. Metformin salts of lipophilic acids
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
EP2384750A1 (en) * 2002-09-27 2011-11-09 Martek Biosciences Corporation Improved Glycemic Control for Prediabetes and/or Diabetes Type II using Docohexaenoic Acid
ITMI20022394A1 (it) 2002-11-13 2004-05-14 Bracco Spa Uso di triiodotironina 3-solfato come farmaco ad attivita' tireomimetica e relative formulazioni farmaceutiche.
EP1605781A1 (en) * 2003-03-18 2005-12-21 Novartis AG Compositions comprising fatty acids and amino acids
EP1510208A1 (en) 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
US20080045559A1 (en) 2003-10-29 2008-02-21 Sonus Pharmaceuticals, Inc. Tocopherol-modified therapeutic drug compounds
DE602004027936D1 (de) 2003-10-29 2010-08-12 Sonus Pharmaceutical Inc Tocopherolmodifizierte therapeutische arzneimittelverbindung
AU2004285532A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Administration of levodopa and carbidopa
EP1708707A1 (en) 2004-01-22 2006-10-11 Neurosearch A/S Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an n-methyl-d-aspartate (nmda) receptors antagonist
WO2005118612A1 (en) 2004-06-04 2005-12-15 Sonus Pharmaceuticals, Inc. Cholesterol/bile acid/bile acid derivative-modified therapeutic anti-cancer drugs
JP5491697B2 (ja) * 2004-10-15 2014-05-14 フォトンズ コーポレイション リミテッド 高レベルオメガ−3および低レベル飽和脂肪酸を含む組成物
WO2006046156A2 (en) 2004-10-29 2006-05-04 Joan Campbell-Tofte Anti-diabetic extract isolated from rauvolfia vomitoria and citrus aurantium, and methods of using same
US20080200533A1 (en) 2005-07-04 2008-08-21 Ramu Krishnan Drug or Pharmaceutical Compounds and a Preparation Thereof
US7666898B2 (en) 2005-11-03 2010-02-23 Ilypsa, Inc. Multivalent indole compounds and use thereof as phospholipase-A2 inhibitors
US20070213298A1 (en) * 2006-02-07 2007-09-13 Universitetet I Oslo Omega 3
JP2009526747A (ja) 2006-02-16 2009-07-23 武田薬品工業株式会社 環状アミン化合物および高血圧の予防・治療のための用途
US20090047340A1 (en) 2006-03-29 2009-02-19 Guilford F Timothy Liposomal reduced glutathione and 1-arginine, including with other ingredient(s), capable of multipath administration for reversal and prevention of obesity and for mitochondrial biogenesis
CN101522658A (zh) 2006-06-16 2009-09-02 因迪基恩药物公司 作为抗糖尿病药用于控制糖尿病高血糖症和糖尿病并发症的二甲双胍r-(+)硫辛酸盐
CN101535238A (zh) 2006-11-01 2009-09-16 普罗诺瓦生物医药挪威公司 作为过氧化物酶体增生物激活受体(PPAR)的活化剂或调节剂的α-取代的ω-3脂质
WO2008053340A1 (en) * 2006-11-03 2008-05-08 Pronova Biopharma Norge As A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent
US20100105773A1 (en) * 2006-11-09 2010-04-29 The Children's Medical Center Corporation Use of resolvins and docosatrienes and analogues thereof for the treatment of angiogenesis and ocular neovascularization
WO2008093984A1 (en) * 2007-01-29 2008-08-07 Hanall Pharmaceutical Company. Ltd N, n- dimethyl imidodicarbonimidic diamide acetate, method for producing the same and pharmaceutical compositions comprising the same
US20090227560A1 (en) 2007-04-27 2009-09-10 Takanobu Kuroita Substituted imidazole compound and use thereof
CL2008001163A1 (es) 2007-04-27 2008-12-19 Takeda Pharmaceutical Compuestos derivados de 1h-imidazo-4-il(piperazibn) metanona, inhibidores de renina superior, composicion farmaceutica que comprende a dichos compuestos; y uso de los compuestos para el tratamiento o prevencion de la hipertension.
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
JP5292404B2 (ja) * 2007-09-21 2013-09-18 ハンオル バイオファーマ カンパニー,リミテッド N,n−ジメチルイミドジカルボンイミド酸ジアミドのジカルボン酸塩、その製造方法、及びその薬剤学的組成物
WO2009051112A1 (ja) 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
ES2645588T3 (es) 2008-05-05 2017-12-05 Oramed Ltd. Métodos y composiciones para la administración oral de exenatida
EA201301040A1 (ru) 2008-06-19 2014-01-30 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение и его применение
AU2010241567B2 (en) * 2009-04-29 2013-10-31 Amarin Pharmaceuticals Ireland Limited Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same
US20110052678A1 (en) 2010-11-05 2011-03-03 Shantha Totada R Method for treating age related macular degeneration
US20120178813A1 (en) 2011-01-12 2012-07-12 Thetis Pharmaceuticals Llc Lipid-lowering antidiabetic agent
CA2916208A1 (en) 2012-06-17 2013-12-27 Matinas Biopharma, Inc. Omega-3 pentaenoic acid compositions and methods of use

Similar Documents

Publication Publication Date Title
JP2014512333A5 (ja)
JP2015523382A5 (ja)
JP7443057B2 (ja) (S)-N-(5-((R)-2-(2,5-ジフルオロフェニル)ピロリジン-1-イル)-ピラゾロ[1,5-a]ピリミジン-3-イル)-3-ヒドロキシピロリジン-1-カルボキサミドの調製
Köppen et al. Solvent-dependent formation of three new Bi-metal–organic frameworks using a tetracarboxylic acid
RU2014110399A (ru) Кристаллические формы вгс протеазного ингибитора
JP2013032389A5 (ja)
JP2019512474A (ja) シアノ置換インドール化合物およびlsd1阻害剤としてのその使用
JP2013525444A5 (ja)
WO2012076466A2 (de) Substituierte 1-benzylcycloalkylcarbonsäuren und ihre verwendung
Sun et al. Strengthening π–π interactions while suppressing Csp2–H··· π (T-shaped) interactions via perfluoroalkylation: A crystallographic and computational study that supports the beneficial formation of 1-D π–π stacked aromatic materials
JP2013518107A5 (ja)
JP2012512197A5 (ja)
JP2011037841A5 (ja)
Croitor et al. Nine Mn (II), Zn (II) and Cd (II) mixed-ligand coordination networks with rigid dicarboxylate and pyridine-n-aldoxime ligands: Impact of the second ligand in the structures’ dimensionality and solvent capacity
JP2012107014A5 (ja)
Choquesillo-Lazarte et al. Halogen bonded cocrystals of active pharmaceutical ingredients: pyrazinamide, lidocaine and pentoxifylline in combination with haloperfluorinated compounds
JP2013541592A5 (ja)
TW201216957A (en) Biarylamide derivative or a pharmaceutically acceptable salt thereof
US9394298B2 (en) Pyrroloquinoline quinone tetraalkali salt and crystal thereof, methods for producing these, and composition
RU2019138773A (ru) Производство транс-[тетрахлорбис(1h-индазол)рутената(iii)] и его композиций
Božić et al. Synthesis, characterization and antiproliferative activity of transition metal complexes with 3-(4, 5-diphenyl-1, 3-oxazol-2-yl) propanoic acid (oxaprozin)
PE20131327A1 (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparacion, y las composiciones farmaceuticas que la contienen
JP2012176989A5 (ja)
JP2018509421A5 (ja)
WO2014008379A3 (en) Diamine and meglumine salt forms of fatty acids